[go: up one dir, main page]

NZ738256B2 - Substituted tetrahydroquinolinone compounds as ror gamma modulators - Google Patents

Substituted tetrahydroquinolinone compounds as ror gamma modulators Download PDF

Info

Publication number
NZ738256B2
NZ738256B2 NZ738256A NZ73825616A NZ738256B2 NZ 738256 B2 NZ738256 B2 NZ 738256B2 NZ 738256 A NZ738256 A NZ 738256A NZ 73825616 A NZ73825616 A NZ 73825616A NZ 738256 B2 NZ738256 B2 NZ 738256B2
Authority
NZ
New Zealand
Prior art keywords
acetamide
phenyl
ethylsulfonyl
tetrahydroquinolinyl
dimethyloxo
Prior art date
Application number
NZ738256A
Other versions
NZ738256A (en
Inventor
Ujjinamatada Ravi Kotrabasaiah
Chetan Pandit
Original Assignee
Aurigene Oncology Limited
Filing date
Publication date
Application filed by Aurigene Oncology Limited filed Critical Aurigene Oncology Limited
Priority claimed from PCT/IB2016/052773 external-priority patent/WO2016185342A1/en
Publication of NZ738256A publication Critical patent/NZ738256A/en
Publication of NZ738256B2 publication Critical patent/NZ738256B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

The present invention provides substituted tetrahydroquinolinone and related compounds of formula (I), which are therapeutically useful as modulators of Retinoic acid receptor-related orphan receptors (RORs), more particularly as ROR? modulators. These compounds are useful in the treatment and prevention of diseases and/or disorder, in particular their use in diseases and/or disorder mediated by ROR? receptor. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted tetrahydroquinolinone or related compounds of formula (I), together with a pharmaceutically acceptable carrier, diluent or excipient therefor.

Claims (16)

We Claim:
1. A compound of formula (I): 5 or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein, ring Het is heterocyclyl; each Y Y and Y are independently CR or N, wherein 0-2 of Y Y and Y are N; 1, 2 3 a 1, 2 3 each Z Z , Z Z and Z are independently CR or N, wherein 0-3 of Z Z , Z Z and Z 1, 2 3, 4 5 a 1, 2 3, 4 5 10 are N; L is *-NR -C(O)-(CR R ) -, *-C(O)-NR -(CR R ) -, *-NR -S(O) -(CR R ) - or *-S(O) - b b c n b b c n b 2 b c n 2 NR -(CR R ) -; wherein the group marked with * is connected to the ring containing Y Y and b b c n 1, 2 each R , R , R and R are independently hydrogen, halo, alkyl, hydroxy, hydroxyalkyl, 1 2 6 7 15 cyano, alkoxy, haloalkyl, haloalkoxy, alkenyl, alkynyl, cycloalkyl, aryl, heteroaryl, -COR or - COOR ; R at each occurrence is independently hydroxy, halo, alkyl, alkylamino, alkoxy, haloalkyl, haloalkoxy or cycloalkyl; alternatively, two R on the same carbon atom together form an oxo (=O) group; 20 R is hydrogen, alkyl or alkoxy; R is alkyl, -(CH ) NR R , hydroxyalkyl, cycloalkyl, aryl or heterocyclyl; 5 2 n b c Ra is hydrogen, alkyl, alkoxy, halo, cycloalkyl or aryl; R and R are each independently hydrogen, alkyl or alkoxyalkyl; alternatively, R and R on the same atom together form a ring; 25 R is hydrogen, alkyl, alkoxy or cycloalkyl; m is 0 to 3; and n is 0 to 3.
2. The compound according to claim 1, is a compound of formula (IA): 5 or a pharmaceutically acceptable salt or a stereoisomer thereof.
3. The compound according to claim 1, is a compound of formula (IB): or a pharmaceutically acceptable salt or a stereoisomer thereof.
4. The compound according to claim 1, is a compound of formula (IC): or a pharmaceutically acceptable salt or a stereoisomer thereof.
5. The compound according to claim 1, is a compound of formula (ID): or a pharmaceutically acceptable salt or a stereoisomer thereof.
6. The compound according to claim 1, is a compound of formula (IE): 5 or a pharmaceutically acceptable salt or a stereoisomer thereof.
7. The compound according to claim 1, is a compound of formula (IF): or a pharmaceutically acceptable salt or a stereoisomer thereof.
8. The compound according to claim 1, is a compound of formula (IG): or a pharmaceutically acceptable salt or a stereoisomer thereof.
9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein ring Het is pyridyl, pyridazinyl, pyridazinone, 5 pyrimidinyl, pyrazinyl, pyrazolyl, imidazopyrazinyl, imidazopyridyl, pyrrolopyrazinyl, thienyl, benzodioxolyl, benzimidazolyl, imidazolyl, imidazopyridazinyl or tetrahydroisoquinolinonyl.
10. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein, is , , , , or . 10
11. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein is or .
12. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein L is *-NHCOCH - or *–CONHCH - wherein the group marked with * is connected to the ring containing Y Y and Y . 1, 2 3 15
13. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein each R R R and R are hydrogen; R is alkyl. 1, 2, 6 7 4
14. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein R is alkyl.
15. The compound according to any one of claims 1 to 11, or a pharmaceutically acceptable salt or a stereoisomer thereof wherein R is hydrogen or alkyl. 5
16. A compound according to claim 1, wherein the compound is selected from: Compound IUPAC Name N-(4,6-dimethyloxo(pyridinyl)-5,6,7,8-tetrahydroquinolinyl)(4- 1 (ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridinyl)methyloxo- 2 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyloxo(6-(trifluoromethyl)pyridin 3 yl)-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridinyl)-7,7-dimethyloxo- 4 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyridinyl)methyloxo- 5 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazinyl)methyloxo- 6 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(2,6-dimethylpyrimidinyl)methyloxo-5,6,7,8-tetrahydroquinolin 7 yl)(4-(ethylsulfonyl)phenyl)acetamide; N-(6-methyloxo(5-(trifluoromethyl)pyridinyl)-5,6,7,8- 8 tetrahydroquinolinyl)(4-(methylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(2-methylimidazo[1,2-a]pyrazinyl)- 9 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(5-chloropyridinyl)methyloxo-5,6,7,8-tetrahydroquinolinyl) 10 (4-(methylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazinyl)-3,6-dimethyl 11 oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 12 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazinyl)methyloxo- 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(imidazo[1,2-a]pyridinyl)methyloxo-5,6,7,8-tetrahydroquinolin 13 yl)(4-(methylsulfonyl)phenyl)acetamide; N-(6-ethyl(imidazo[1,2-a]pyrazinyl)oxo-5,6,7,8-tetrahydroquinolin 14 yl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyloxo(pyrrolo[1,2-a]pyrazinyl)- 15 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(6-methylimidazo[1,2-a]pyrazinyl)- 16 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridinyl)-4,6-dimethyloxo- 17 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(4,6-dimethyloxo(pyridinyl)-5,6,7,8-tetrahydroquinolinyl)(4- 18 (ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridinyl)-4,6-dimethyloxo- 19 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridinyl)-4,6-dimethyloxo- 20 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyrimidinyl)-4,6-dimethyloxo- 21 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-methoxypyridinyl)-4,6-dimethyloxo- 22 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoropyridinyl)-4,6-dimethyloxo- 23 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(5-chloromethoxypyridinyl)-4,6-dimethyloxo-5,6,7,8- 24 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxypyrimidinyl)-4,6-dimethyloxo- 25 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazinyl)-4,6-dimethyl 26 oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 27 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrazinyl)-4,6-dimethyloxo- 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(2,6-dimethylpyrimidinyl)-4,6-dimethyloxo-5,6,7,8- 28 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(6-(4,6-dimethylpyrimidinyl)-4,6-dimethyloxo-5,6,7,8- 29 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxypyrimidinyl)-4,6-dimethyloxo- 30 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazinyl)-4,6-dimethyloxo- 31 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(4,6-dimethyloxo(5-(trifluoromethyl)pyridinyl)-5,6,7,8- 32 tetrahydroquinolinyl)(4-(methylsulfonyl)phenyl)acetamide; N-(6-(imidazo[1,2-a]pyrazinyl)-4,6-dimethyloxo-5,6,7,8- 33 tetrahydroquinolinyl)(4-(methylsulfonyl)phenyl)acetamide; N-(4,6-dimethyl(6-methylpyridazinyl)oxo-5,6,7,8-tetrahydroquinolin 34 yl)(4-(ethylsulfonyl)phenyl)acetamide; N-(6-(6-methoxypyridazinyl)-4,6-dimethyloxo-5,6,7,8-tetrahydroquinolin- 35 2-yl)(4-(methylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(4-hydroxypyrimidinyl)-4,6-dimethyloxo- 36 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridinyl)-4,6-dimethyloxo- 37 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(5-chlorohydroxypyridinyl)-4,6-dimethyloxo-5,6,7,8- 38 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-hydroxypyridinyl)-4,6-dimethyloxo- 39 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-hydroxypyridinyl)methyloxo- 40 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(6-ethylpyridazinyl)methyloxo-5,6,7,8-tetrahydroquinolinyl) 41 (4-(ethylsulfonyl)phenyl)acetamide; 42 N-(6-(benzo[d][1,3]dioxolyl)-4,6-dimethyloxo-5,6,7,8-tetrahydroquinolin yl)(4-(ethylsulfonyl)phenyl)acetamide; N-(4,6-dimethyl(1-methyl-1H-benzo[d]imidazolyl)oxo-5,6,7,8- 43 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(4,6-dimethyl(2-methyloxo-1,2,3,4-tetrahydroisoquinolinyl)oxo- 44 5,6,7,8-tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(5-methylthiophenyl)oxo- 45 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(3,5-dimethyl-1H-pyrazolyl)methyloxo-5,6,7,8-tetrahydroquinolin- 46 2-yl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyloxo(1H-pyrazolyl)-5,6,7,8- 47 tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazinyl)-6,8-dimethyl 48 oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(3-methylimidazo[1,2-a]pyrazinyl)- 49 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-isopropylpyrimidinyl)methyloxo- 50 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(2,6-dimethylimidazo[1,2-a]pyrazinyl)methyloxo-5,6,7,8- 51 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(4,6-dimethyl(2-methylimidazo[1,2-a]pyrazinyl)oxo-5,6,7,8- 52 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(4,6-dimethyloxo(6-(trifluoromethyl)pyridazinyl)-5,6,7,8- 53 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-a]pyrazinyl)methyloxo- 54 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyloxo(6-(trifluoromethyl)pyridazin- 55 3-yl)-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidinyl)methyloxo- 56 5,6,7,8-tetrahydroquinolinyl)acetamide; 57 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-isopropoxypyridazinyl)methyloxo- 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)fluorophenyl)-N-(6-methyl(2-methylimidazo[1,2- 58 a]pyrazinyl)oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-methyl(2-methylimidazo[1,2-a]pyrazinyl)oxo-5,6,7,8- 59 tetrahydroquinolinyl)(4-(methylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-isopropylpyrazinyl)methyloxo- 60 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidinyl)-4,6-dimethyloxo- 61 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-isopropylpyridazinyl)methyloxo- 62 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(6-ethylpyridazinyl)-4,6-dimethyloxo-5,6,7,8-tetrahydroquinolin 63 yl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxymethylpyrimidinyl)methyl- 64 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxymethylpyrimidinyl)methyl- 65 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoromethylimidazo[1,2-a]pyrazinyl)- 66 6-methyloxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(2-methyl(trifluoromethyl)- 67 pyrimidinyl)oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(5-methylimidazo[1,2-a]pyrazinyl)- 68 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(2,6-dimethylpyrimidinyl)-7,7-dimethyloxo-5,6,7,8- 69 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(4,6-dimethyl(1-methyloxo-1,6-dihydropyridazinyl)oxo-5,6,7,8- 70 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(6-(3-cyclopropylimidazo[1,2-a]pyrazinyl)methyloxo-5,6,7,8- 71 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 72 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyloxo(2-(trifluoromethyl)- imidazo[1,2-a]pyrazinyl)-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyridazinyl)-4,6-dimethyloxo- 73 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyloxo(3-(trifluoromethyl)- 74 imidazo[1,2-a]pyrazinyl)-5,6,7,8-tetrahydroquinolinyl)acetamide; N-(4,6-dimethyl(2-methylimidazo[1,2-b]pyridazinyl)oxo-5,6,7,8- 75 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(6-(5-cyclopropylmethoxypyridazinyl)-4,6-dimethyloxo-5,6,7,8- 76 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(imidazo[1,2-b]pyridazinyl)-4,6-dimethyl 77 oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(6-methyl(trifluoromethyl)- 78 pyrimidinyl)oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(2,6-dimethylpyrimidinyl)methyloxo-5,6,7,8-tetrahydroquinolin 79 yl)(5-(ethylsulfonyl)pyridinyl)acetamide; 2-(5-(ethylsulfonyl)pyridinyl)-N-(6-(6-methoxypyridazinyl)-4,6-dimethyl 80 oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(2,6-dimethylpyrimidinyl)-6,7-dimethyloxo-5,6,7,8- 81 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(6-(2,6-dimethylpyrimidinyl)methyloxo-5,6,7,8-tetrahydroquinolin 82 yl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxypyridinyl)-4,6-dimethyloxo- 84 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridinyl)-4,6-dimethyloxo- 85 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-hydroxymethylpyridinyl)-4,6-dimethyl- 86 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridinyl)-7,7-dimethyloxo- 87 5,6,7,8-tetrahydroquinolinyl)acetamide; 88 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-hydroxypyridinyl)-4,6-dimethyloxo- 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(3-hydroxypyridinyl)-4,6-dimethyloxo-5,6,7,8-tetrahydroquinolin 89 yl)(4-(methylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-hydroxypyridinyl)-7,7-dimethyloxo- 90 5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridinyl)methyloxo- 91 5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(5-chloroimidazo[1,2-a]pyrazinyl)methyloxo-5,6,7,8- 92 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; N-(6-(6-chloropyridazinyl)methyloxo-5,6,7,8-tetrahydroquinolinyl) 93 (4-(ethylsulfonyl)phenyl)acetamide; 3-(2-(2-(4-(ethylsulfonyl)phenyl)acetamido)-4,6-dimethyloxo-5,6,7,8- 94 tetrahydroquinolinyl)methoxypyridazine 1-oxide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxymethylpyridazinyl)-4,6- 95 dimethyloxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxymethylpyridazinyl)-4,6- 96 dimethyloxo-5,6,7,8-tetrahydroquinolinyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-fluoroimidazo[1,2-a]pyrazinyl)methyl- 97 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; N-(6-(6-(dimethylamino)pyridazinyl)-4,6-dimethyloxo-5,6,7,8- 98 tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; 6-(2,6-dimethylpyrimidinyl)-N-(4-(ethylsulfonyl)benzyl)methyloxo- 99 5,6,7,8-tetrahydroquinolinecarboxamide; N-(6-(2,6-dimethylpyrimidinyl)methyloxo-5,6,7,8-tetrahydronaphthalen- 100 2-yl)(4-(ethylsulfonyl)phenyl)acetamide; 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridinyl)-4,6-dimethyloxo- 101 5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-85); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(3-hydroxypyridinyl)-4,6-dimethyloxo- 102 5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-2 of Compound-85); 103 N-(6-(2,6-dimethylpyrimidinyl)methyloxo-5,6,7,8-tetrahydroquinolin yl)(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of Compound-7); N-(6-(2,6-dimethylpyrimidinyl)methyloxo-5,6,7,8-tetrahydroquinolin 104 yl)(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of Compound-7); 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(2-methylimidazo[1,2-a]pyrazinyl)- 105 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-9); 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(2-methylimidazo[1,2-a]pyrazinyl)- 106 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-2 of Compound-9); N-(6-(2,6-dimethylpyrimidinyl)-4,6-dimethyloxo-5,6,7,8- tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-1 of 107 Compound-28); N-(6-(2,6-dimethylpyrimidinyl)-4,6-dimethyloxo-5,6,7,8- tetrahydroquinolinyl)(4-(ethylsulfonyl)phenyl)acetamide; (Isomer-2 of 108 Compound-28); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazinyl)-4,6-dimethyloxo- 109 5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-31); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxypyridazinyl)-4,6-dimethyloxo- 110 5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-2 of Compound-31); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidinyl)methyloxo- 111 5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-56); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(5-methoxypyrimidinyl)methyloxo- 112 5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-2 of Compound-56); 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(3-methylimidazo[1,2-a]pyrazinyl)- 113 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-49); 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(3-methylimidazo[1,2-a]pyrazinyl)- 114 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-2 of Compound-49); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxymethylpyrimidinyl)methyl- 115 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-65); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(6-methoxymethylpyrimidinyl)methyl- 116 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-2 of Compound-65); 117 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(6-methylimidazo[1,2-a]pyrazinyl)- 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-16); 2-(4-(ethylsulfonyl)phenyl)-N-(6-methyl(6-methylimidazo[1,2-a]pyrazinyl)- 118 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-2 of Compound-16); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxymethylpyrimidinyl)methyl- 119 5-oxo-5,6,7,8-tetrahydroquinolinyl)acetamide; (Isomer-1 of Compound-64); 2-(4-(ethylsulfonyl)phenyl)-N-(6-(2-methoxymethylpyrimidinyl)methyl-
NZ738256A 2016-05-13 Substituted tetrahydroquinolinone compounds as ror gamma modulators NZ738256B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2448CH2015 2015-05-15
PCT/IB2016/052773 WO2016185342A1 (en) 2015-05-15 2016-05-13 Substituted tetrahydroquinolinone compounds as ror gamma modulators

Publications (2)

Publication Number Publication Date
NZ738256A NZ738256A (en) 2024-09-27
NZ738256B2 true NZ738256B2 (en) 2025-01-07

Family

ID=

Similar Documents

Publication Publication Date Title
CN111886224B (en) Heterocyclic inhibitors of ATR kinase
AU2023202125B2 (en) Pyridazinones and methods of use thereof
CA3135555C (en) Protein tyrosine phosphatase inhibitors
AU2018301696B2 (en) Heterocyclic inhibitors of ATR kinase
CA2988601C (en) Bicyclic lactams and methods of use thereof
RU2020124136A (en) CHROMENOPYRIDINE DERIVATIVES AS PHOSPHATIDILINOSITOLPHOSPHATKINASE INHIBITORS
CA3137458A1 (en) Fgfr inhibitors and methods of use thereof
AU2020306124A1 (en) Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
AU2018243770A1 (en) Isoquinolines as inhibitors of HPK1
JP2024056755A5 (en)
IL275522B1 (en) Amine derivatives of ARYL–BIPYRIDINE as phosphatidylinositol phosphate kinase inhibitors
CA2931758A1 (en) Fused tricyclic imidazole derivatives as modulators of tnf activity
KR20140107421A (en) Use of inhibitors of the activity or function of PI3K
CA2779303A1 (en) Bicyclic pyridines and analogs as sirtuin modulators
ME02104B (en) Apoptosis signal-regulating kinase inhibitors
WO2011035518A1 (en) Pyrimidine derivatives and analogs, preparation method and use thereof
WO2020012357A1 (en) Heterocyclic compounds and methods of use
CA2975291A1 (en) Substituted bridged urea analogs as sirtuin modulators
WO2024035950A1 (en) Inhibitors of kif18a and uses thereof
CN112218631A (en) Heterocyclic inhibitors of ATR kinase
AU2020332462A1 (en) Azaheteroaryl compound and application thereof
RU2656853C2 (en) Pyrrol[2,3-b]pyrazines as syk inhibitors
WO2013042035A4 (en) Heterocyclic compounds as inhibitors of fatty acid biosynthesis for bacterial infections
JP2013515710A5 (en)
EP4584250A1 (en) Combination therapies including metal channel activators